Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Change in Accured Expenses (2016 - 2026)

Champions Oncology (CSBR) has 16 years of Change in Accured Expenses data on record, last reported at $388000.0 in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 183.21% year-over-year to $388000.0; the TTM value through Oct 2025 reached -$46000.0, down 121.9%, while the annual FY2025 figure was $395000.0, 462.39% up from the prior year.
  • Change in Accured Expenses reached $388000.0 in Q4 2025 per CSBR's latest filing, up from -$755000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $405000.0 in Q1 2024 and bottomed at -$755000.0 in Q3 2025.
  • Average Change in Accured Expenses over 5 years is -$18894.7, with a median of $15000.0 recorded in 2021.
  • Peak YoY movement for Change in Accured Expenses: tumbled 3140.0% in 2022, then surged 304.48% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$335000.0 in 2021, then grew by 14.33% to -$287000.0 in 2022, then surged by 76.66% to -$67000.0 in 2023, then soared by 304.48% to $137000.0 in 2024, then surged by 183.21% to $388000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $388000.0 in Q4 2025, -$755000.0 in Q3 2025, and $289000.0 in Q2 2025.